These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35349715)

  • 1. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab.
    Goto T; Miyazaki Y; Nakayamada S; Shiraishi N; Yoshinaga T; Tanaka Y; Nakamura T
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):237-242. PubMed ID: 35349715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
    Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial Mediterranean fever, review of the literature.
    Alghamdi M
    Clin Rheumatol; 2017 Aug; 36(8):1707-1713. PubMed ID: 28624931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab for the treatment of familial Mediterranean fever.
    Ozdogan H; Ugurlu S
    Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
    Front Immunol; 2020; 11():971. PubMed ID: 32670263
    [No Abstract]   [Full Text] [Related]  

  • 8. Familial Mediterranean fever: overview of pathogenesis, clinical features and management.
    Migita K; Asano T; Sato S; Koga T; Fujita Y; Kawakami A
    Immunol Med; 2018 Jun; 41(2):55-61. PubMed ID: 30938266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
    Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial Mediterranean Fever.
    Ozdogan H; Ugurlu S
    Presse Med; 2019 Feb; 48(1 Pt 2):e61-e76. PubMed ID: 30686512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
    Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
    Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
    Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O
    Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.
    Giat E; Ben-Zvi I; Lidar M; Livneh A
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine.
    Roldan R; Ruiz AM; Miranda MD; Collantes E
    Joint Bone Spine; 2008 Jul; 75(4):504-5. PubMed ID: 18541452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: A Pediatric Case of Familial Mediterranean Fever Concurrent With Autoimmune Hepatitis.
    Aoki M; Izawa K; Tanaka T; Honda Y; Shiba T; Maeda Y; Miyamoto T; Okamoto K; Nishitani-Isa M; Nihira H; Imai K; Takita J; Nishikomori R; Hiejima E; Yasumi T
    Front Immunol; 2022; 13():917398. PubMed ID: 35812376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
    Meinzer U; Quartier P; Alexandra JF; Hentgen V; Retornaz F; Koné-Paut I
    Semin Arthritis Rheum; 2011 Oct; 41(2):265-71. PubMed ID: 21277619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.